Circle has introduced cirBTC, a new wrapped Bitcoin asset on Ethereum, backed 1:1 by segregated Bitcoin custody and verified via Chainlink Proof of Reserve for transparency. Issued through Circle's Bermuda-regulated entity, cirBTC aims to appeal to institutional investors seeking clear custody and compliance standards. The asset enters a competitive market dominated by WBTC and Coinbase's cbBTC, with its success hinging on gaining liquidity and integration into major DeFi platforms. Circle leverages its existing stablecoin infrastructure to build trust and adoption for cirBTC in decentralized finance.
Oculis Holding AG has completed patient randomization in its PREDICT-1 clinical trial testing Licaminlimab, a precision medicine targeting TNFR1-mediated dry eye disease (DED). Two-thirds of the 176 enrolled patients carry a genetic variant linked to...
Ekalia, a joint venture between IBA and Framatome, has signed a collaboration agreement with Telix Pharmaceuticals to accelerate the production of astatine-211 in the United States. Astatine-211 is a promising alpha-emitting radioisotope used in targ...
At ESMO 2026, Roche presented key Phase III trial results showcasing significant advances in cancer treatment. Divarasib demonstrated superior efficacy over first-generation KRAS G12C inhibitors in advanced lung cancer, potentially setting a new stan...
Red Cat Holdings announced a voluntary public purchase offer to acquire all outstanding shares of Steyr Motors AG at €39 per share in cash, representing a significant premium over recent prices. The acquisition aims to strengthen Red Cat's Blue Ops u...
GSK announced that its experimental lung cancer drug, risvutatug rezetecan, achieved a 61% confirmed response rate at the higher 8 mg/kg dose in an early global trial involving patients with relapsed extensive-stage small cell lung cancer. This respo...
